TY - JOUR
T1 - Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine
T2 - a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association
AU - Biondi, B.
AU - Bartalena, L.
AU - Chiovato, L.
AU - Lenzi, A.
AU - Mariotti, S.
AU - Pacini, F.
AU - Pontecorvi, A.
AU - Vitti, P.
AU - Trimarchi, F.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Levothyroxine (L-T4) is recommended as lifelong replacement therapy for hypothyroidism. Recent clinical and experimental data support the addition of levotriiodothyronine (L-T3) treatment in some selected hypothyroid patients when their symptoms persist and their quality of life remains impaired despite adequate L-T4 monotherapy. An increase in L-T3 prescriptions has been recently observed in Italy due to availability of different L-T3 formulations, making it possible to clinicians to prescribe L-T3 alone or in combination with L-T4. The aim of the present position statement was to define the correct clinical indications, schedule, duration of treatment and contraindications of combined treatment with L-T4 and L-T3 in hypothyroid patients in an attempt to guide clinicians and to avoid potential adverse effects of overtreatment.
AB - Levothyroxine (L-T4) is recommended as lifelong replacement therapy for hypothyroidism. Recent clinical and experimental data support the addition of levotriiodothyronine (L-T3) treatment in some selected hypothyroid patients when their symptoms persist and their quality of life remains impaired despite adequate L-T4 monotherapy. An increase in L-T3 prescriptions has been recently observed in Italy due to availability of different L-T3 formulations, making it possible to clinicians to prescribe L-T3 alone or in combination with L-T4. The aim of the present position statement was to define the correct clinical indications, schedule, duration of treatment and contraindications of combined treatment with L-T4 and L-T3 in hypothyroid patients in an attempt to guide clinicians and to avoid potential adverse effects of overtreatment.
UR - http://www.scopus.com/inward/record.url?scp=84994877396&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994877396&partnerID=8YFLogxK
U2 - 10.1007/s40618-016-0511-z
DO - 10.1007/s40618-016-0511-z
M3 - Article
AN - SCOPUS:84994877396
VL - 39
SP - 1465
EP - 1474
JO - Journal of Endocrinological Investigation
JF - Journal of Endocrinological Investigation
SN - 0391-4097
IS - 12
ER -